Kuros Biosciences AG
CSBTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $76 | $34 | $18 | $14 |
| % Growth | 125.1% | 86.6% | 30.2% | – |
| Cost of Goods Sold | $14 | $5 | $7 | $4 |
| Gross Profit | $62 | $28 | $11 | $10 |
| % Margin | 82.1% | 84.8% | 59.9% | 72.9% |
| R&D Expenses | $7 | $6 | $5 | $5 |
| G&A Expenses | $5 | $4 | $3 | $3 |
| SG&A Expenses | $41 | $21 | $11 | $7 |
| Sales & Mktg Exp. | $36 | $17 | $8 | $5 |
| Other Operating Expenses | $19 | $15 | $8 | $6 |
| Operating Expenses | $67 | $42 | $24 | $19 |
| Operating Income | -$5 | -$13 | -$13 | -$9 |
| % Margin | -6.6% | -39.3% | -74.8% | -63.5% |
| Other Income/Exp. Net | $2 | $3 | -$3 | -$1 |
| Pre-Tax Income | -$3 | -$10 | -$16 | -$10 |
| Tax Expense | $0 | $0 | -$1 | -$2 |
| Net Income | -$4 | -$14 | -$15 | -$8 |
| % Margin | -4.9% | -40.9% | -81.1% | -54.6% |
| EPS | -0.1 | -0.38 | -0.43 | -0.23 |
| % Growth | 73.7% | 11.6% | -87% | – |
| EPS Diluted | -0.1 | -0.38 | -0.43 | -0.23 |
| Weighted Avg Shares Out | 37 | 37 | 34 | 33 |
| Weighted Avg Shares Out Dil | 37 | 37 | 34 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $1 |
| Interest Expense | $0 | -$2 | $4 | $1 |
| Depreciation & Amortization | $3 | $2 | $2 | $3 |
| EBITDA | -$1 | -$7 | -$8 | -$5 |
| % Margin | -0.7% | -22.3% | -41.7% | -38.3% |